Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong

Lai, Francisco Tsz Tsun; Huang, Lei; Chui, Celine Sze Ling; Wan, Eric Yuk Fai; Li, Xue; Wong, Carlos King Ho; Chan, Edward W.; Ma, Tiantian; Lum, Dawn Hei; Leung, Janice Ching Nam; Luo, Hao; Chan, Esther Wai Yin; Wong, Ian C. K.

doi:10.1038/s41467-022-28068-3

Cited by 73 publications

(69 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As of 31st August 2021, 2,811,500 doses of CoronaVac (37.05%) and 4,776,700 doses of BioNTech (62.95%) have been administered [ 5 ]. The mean age of the individuals vaccinated with CoronaVac was 61.58 (SD: 11.08) and with Comirnaty was 56.81 (SD: 13.43) [ 6 ]. The proportion of male in individuals vaccinated with CoronaVac was 48.7% and with BioNTech was 47.4% [ 6 ].…”

Section: Resultsmentioning

confidence: 99%

“…The mean age of the individuals vaccinated with CoronaVac was 61.58 (SD: 11.08) and with Comirnaty was 56.81 (SD: 13.43) [ 6 ]. The proportion of male in individuals vaccinated with CoronaVac was 48.7% and with BioNTech was 47.4% [ 6 ]. 42 patients developed myopericarditis within 14 days after vaccination, 16 of which belonged to the 12–15 age group.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study

et al. 2022

View full text Add to dashboard Cite

Background Both COVID-19 infection and COVID-19 vaccines have been associated with the development of myopericarditis. The objective of this study is to (1) analyse the rates of myopericarditis after COVID-19 infection and COVID-19 vaccination in Hong Kong, (2) compared to the background rates, and (3) compare the rates of myopericarditis after COVID-19 vaccination to those reported in other countries. Methods This was a population-based cohort study from Hong Kong, China. Patients with positive RT-PCR test for COVID-19 between 1st January 2020 and 30th June 2021 or individuals who received COVID-19 vaccination until 31st August were included. The main exposures were COVID-19 positivity or COVID-19 vaccination. The primary outcome was myopericarditis. Results This study included 11,441 COVID-19 patients from Hong Kong, four of whom suffered from myopericarditis (rate per million: 326; 95% confidence interval [CI] 127–838). The rate was higher than the pre-COVID-19 background rate in 2019 (rate per million: 5.5, 95% CI 4.1–7.4) with a rate ratio of 55.0 (95% CI 21.4–141). Compared to the background rate, the rate of myopericarditis among vaccinated subjects in Hong Kong was similar (rate per million: 5.5; 95% CI 4.1–7.4) with a rate ratio of 0.93 (95% CI 0.69–1.26). The rates of myocarditis after vaccination in Hong Kong were comparable to those vaccinated in the United States, Israel, and the United Kingdom. Conclusions COVID-19 infection was associated with significantly higher rate of myopericarditis compared to the vaccine-associated myopericarditis. Graphical abstract

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Recent evidence showed that the efficacy in preventing hospital admission and the prevalence of side effects of CoronaVac and Comirnaty were similar when comparing younger and older people [ 46 , 47 , 48 ]. Moreover, a study among Hong Kong people showed that presence of a chronic condition would not lead to more side effects of COVID-19 vaccination [ 49 ]. There was no evidence showing that COVID-19 vaccination would negatively affect the control of chronic diseases.…”

Section: Discussionmentioning

confidence: 99%

Governmental Incentives, Satisfaction with Health Promotional Materials, and COVID-19 Vaccination Uptake among Community-Dwelling Older Adults in Hong Kong: A Random Telephone Survey

Wang

Fang

et al. 2022

Vaccines

View full text Add to dashboard Cite

COVID-19 vaccination is proven to be effective and safe for older adults. This study investigated the impacts of incentives and health promotional materials provided by the government on the completion of the primary COVID-19 vaccination series among older adults in Hong Kong. Participants were Chinese-speaking community-dwelling adults aged ≥65 years. Telephone numbers were randomly selected from up-to-date Hong Kong telephone directories. A total of 440 participants completed the telephone interview. Logistic regression models were fitted. Among the participants, 58.4% had completed the primary COVID-19 vaccination series. Most participants believed that incentives provided by the government had almost no impact on increasing their motivation to receive COVID-19 vaccination, and less than half thought that vaccination promotional materials produced by the government could address their concerns and help them make decisions. After adjustment for significant background characteristics, we found perceived higher impacts of the incentives and belief that vaccination promotional materials produced by the government could address their concern and were helpful for them to make decisions to be associated with a higher rate of completion of primary COVID-19 vaccination series. Perceptions supporting COVID-19 vaccination and less decisional conflict regarding the choice of vaccine were also positively associated with the dependent variable. Government should develop incentives and health promotional materials tailored to the needs of older adults.

show abstract

“…Accordingly, we removed those who died before the index date, were hospitalized on the index date (in the unvaccinated group) or had any AESI records before the index date. This approach has been used in previous large-scale pharmacovigilance studies as well [ 17 , 20 , 21 ].…”

Section: Methodsmentioning

confidence: 99%

Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study

Lai

Chua

Chan

et al. 2022

Emerging Microbes & Infections

Self Cite

View full text Add to dashboard Cite

Accruing evidence suggests an increased risk of myocarditis in adolescents from messenger RNA COVID-19 vaccines. However, other potential adverse events remain under-researched. We conducted a retrospective cohort study of adolescents aged 12–18 with a territory-wide electronic healthcare database of the Hong Kong population linked with population-based vaccination records and supplemented with age- and sex-specific population numbers. Two age- and sex-matched retrospective cohorts were formed to observe 28 days following the first and second doses of BNT162b2 and estimate the age- and sex-adjusted incidence rate ratios between the vaccinated and unvaccinated. Thirty AESIs adapted from the World Health Organization’s Global Advisory Committee on Vaccine Safety were examined. Eventually, the first-dose cohort comprised 274,881 adolescents (50.25% received the first dose) and the second-dose cohort 237,964 (50.29% received the second dose). Ninety-four (34.2 per 100,000 persons) adolescents in the first-dose cohort and 130 (54.6 per 100,000 persons) in the second-dose cohort experienced ≥1 AESIs. There were no statistically significant differences in the risk of any AESI associated with BNT162b2 except myocarditis [first-dose cohort: incidence rate ratio (IRR) = 9.15, 95% confidence interval (CI) 1.14–73.16; second-dose cohort: IRR = 29.61, 95% CI 4.04–217.07] and sleeping disturbances/disorders after the second dose (IRR = 2.06, 95% CI 1.01–4.24). Sensitivity analysis showed that, with myocarditis excluded as AESIs, no significantly elevated risk of AESIs as a composite outcome associated with vaccination was observed ( P = 0.195). To conclude, the overall absolute risk of AESIs was low with no evidence of an increased risk of AESIs except myocarditis and sleeping disturbances/disorders.

show abstract

Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong

Cited by 73 publications

References 40 publications

Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study

Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study

Governmental Incentives, Satisfaction with Health Promotional Materials, and COVID-19 Vaccination Uptake among Community-Dwelling Older Adults in Hong Kong: A Random Telephone Survey

Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study

Contact Info

Product

Resources

About